Dicot Pharma

0.31

SEK

+2.48 %

Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+2.48%

+7.45%

+27.84%

+36.56%

+87.2%

+109.7%

-1.83%

-54.64%

-87.87%

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.

Market cap

551.42M SEK

Turnover

1.73M SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

29/4

2025

Interim report Q1'25

6/5

2025

General meeting '25

12/8

2025

Interim report Q2'25

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release3/26/2025, 12:43 PM

Dicot Pharma AB: Sista dag för handel med teckningsoptioner TO 6 i Dicot Pharma imorgon 27 mars

Regulatory press release3/26/2025, 12:43 PM

Dicot Pharma AB: Last day of trading in Dicot Pharma TO 6 warrants tomorrow, March 27

Press release3/17/2025, 2:34 PM

Dicot Pharma AB: Dicot Pharma bjuder in till frågestund om TO 6

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/17/2025, 2:34 PM

Dicot Pharma AB: Dicot Pharma invites to a Q&A session on TO 6

Regulatory press release3/17/2025, 7:15 AM

Dicot Pharma AB: Nyttjandeperioden för teckningsoptioner TO 6 i Dicot Pharma inleds idag

Regulatory press release3/17/2025, 7:15 AM

Dicot Pharma AB: Exercise Period for Warrants TO6 in Dicot Pharma Begins Today

Regulatory press release3/13/2025, 10:50 AM

Dicot Pharma AB: Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma's TO 6, Running Until March 31, 2025

Regulatory press release3/13/2025, 10:50 AM

Dicot Pharma AB: Avsiktsförklaringar från större ägare, styrelse och ledning att teckna för 11 miljoner kronor i Dicot Pharmas TO 6 som pågår till 31 mars 2025

Regulatory press release3/11/2025, 7:30 AM

Dicot Pharma AB: Subscription Price SEK 0.38 for Warrants TO 6 in Dicot Pharma Determined; corresponding to SEK 0.19 per share

Regulatory press release3/11/2025, 7:30 AM

Dicot Pharma AB: Teckningskursen för teckningsoptioner TO 6 i Dicot Pharma fastställd till 0,38 kronor - motsvarar 0,19 kronor per aktie

Press release3/6/2025, 11:55 AM

Dicot Pharma AB: Dicot Pharma till Stora Aktiedagarna 11 mars

Press release2/26/2025, 11:39 AM

Dicot Pharma AB: Professor efter ESSM: "Intresset för Dicot Pharmas arbete fortsätter växa"

Press release2/26/2025, 11:39 AM

Dicot Pharma AB: Professor after ESSM: "The interest in Dicot Pharma's work continues to grow"

Regulatory press release2/13/2025, 7:25 AM

Dicot Pharma AB Year-End Report 2024

Regulatory press release2/13/2025, 7:25 AM

Dicot Pharma AB bokslutskommuniké 2024

Regulatory press release2/7/2025, 9:45 AM

Dicot Pharma AB: Nu har hälften av deltagarna i Dicot Pharmas fas 2a-studie doserats

Press release2/5/2025, 9:40 AM

Dicot Pharma AB: Nu har hälften av deltagarna i Dicot Pharmas fas 2a-studie doserats

Press release2/5/2025, 9:40 AM

Dicot Pharma AB: Half of the participants now dosed in Dicot Pharma's Phase 2a study

Regulatory press release12/19/2024, 9:11 AM

Dicot Pharma AB: Hel patentfamilj godkänns i USA

Regulatory press release12/19/2024, 9:11 AM

Dicot Pharma AB: Entire Patent Family Reaching Approval in the United States

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.